Ajinomoto to produce potential COVID-19 treatment for CytoDyn

By Ben Hargreaves

- Last updated on GMT

(Image: Getty/Duncan Andison)
(Image: Getty/Duncan Andison)

Related tags Ajinomoto Bio-Pharma CytoDyn COVID-19 Coronavirus Leronlimab

Ajinomoto agrees partnership to manufacture leronlimab, which is currently undergoing clinical trials for the treatment of COVID-19.

CytoDyn’s potential treatment, leronlimab, is currently being tested for patients deemed ‘mild-to-moderately ill’ and ‘severely ill’ with COVID-19.

According to the company, the treatment is being administered to patients in the New York City area as part of Phase I, Phase III, and Phase IIb/III clinical trials.

In order to ensure supply, CytoDyn has signed an extended manufacturing agreement with Ajinomoto Bio-Pharma Services for aseptic fill-finish services.

The two partners had already been working together for production of leronlimab for other therapeutics indications.

CytoDyn is exploring the monoclonal antibody for use across a variety of indications, including against HIV as both a monotherapy and as part of a combination treatment, which are both at the Phase III stage.

The company has also taken the treatment to Phase II stage for triple-negative breast cancer and Phase II against a total of 22 solid tumor types.

Leronlimab blocks the CCR5 cellular receptor, which is thought to play a role in tumor metastases and is an indicator of disease status in some cancers. It also plays a role in inflammatory conditions by modulating immune cell trafficking to areas of inflammation, the company suggested.

Yesterday, CytoDyn announced that it had submitted a request to the US Food and Drug Administration for ‘compassionate use’ of patients currently ineligible for its two ongoing clinical trials for COVID-19 patients. Currently, the company has 49 patients enrolled for treatment.

Related news

Show more

Related products

show more

Trends in Biopharmaceutical Raw Material Selection

Trends in Biopharmaceutical Raw Material Selection

Actylis – The Partner of Choice | 31-Jan-2023 | Business Advice

Join us as our in-house experts, along with Cecile Bellamy from Pfizer, discuss current and future trends in biopharmaceutical raw material selection.

eBook: mRNA prospects and scale-up solutions

eBook: mRNA prospects and scale-up solutions

Thermo Fisher Scientific - Biosciences | 01-Jan-2023 | Insight Guide

This mRNA eBook was created by Thermo Fisher Scientific, in collaboration with Genetic Engineering & Biotechnology News (GEN), to provide you with...

Create Better Biologic Treatments with Catalent

Create Better Biologic Treatments with Catalent

Catalent | 06-Dec-2022 | Product Brochure

Your biologics possess a high level of complexities and technical challenges. That’s why development is key to ensuring the successful delivery of your...

Related suppliers

Follow us


View more